Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2028

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

Contrast-Enhanced Mammography (CEM)

The intervention involves the use of contrast-enhanced mammography (CEM) to supplement standard mammography for breast cancer screening. This method utilizes iodinated contrast medium to enhance the visualization of breast lesions by assessing tumor neovascularization. CEM will be offered to women with dense breast tissue who are currently awaiting supplemental ultrasound screening. It is designed to be performed in conjunction with regular mammography, offering a more efficient and cost-effective alternative to MRI, with comparable sensitivity in detecting breast cancer. Participants will undergo the CEM procedure in a single visit, allowing for reduced wait times and improved detection rates compared to traditional methods. The procedure is well-tolerated, with minimal side effects, and provides a quicker and more accessible option for supplemental breast cancer screening.

Trial Locations (1)

K1H 9L6

The Ottawa Hospital, Ottawa

All Listed Sponsors
collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

Jean Seely

OTHER

NCT06993246 - Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit? | Biotech Hunter | Biotech Hunter